Beyond Osimertinib: The Development of Third-Generation EGFR Tyrosine Kinase Inhibitors For Advanced EGFR+ NSCLC

Area of Science:

• Oncology
• Pharmacology
• Clinical Trials

Background:

• Osimertinib is the current standard for first-line treatment of advanced EGFR+ NSCLC.
• Almonertinib, a third-generation EGFR TKI, was approved in China in March 2020 for specific NSCLC cases.
• The landscape of third-generation EGFR TKIs is rapidly evolving with new agents in development.

Purpose of the Study:

• To review third-generation EGFR TKIs in late-stage clinical development.
• To summarize interim and phase 3 trial results of these novel agents.
• To profile combination trial designs that may establish new standards of care.

Main Methods:

• Review of interim results from phase 1 and 2 trials of third-generation EGFR TKIs.
• Inclusion of phase 3 trial designs and chemical structures where available.
• Search of clinical trial registration websites for pipeline agents and summary of previously reported trial results.

Main Results:

• Profiling of multiple third-generation EGFR TKIs in late-stage development (e.g., almonertinib, lazertinib, abivertinib).
• Summary of clinical trial outcomes for agents like rociletinib and olmutinib.
• Overview of ongoing combination trials (e.g., FLAURA2, MARIPOSA) exploring novel treatment paradigms.

Conclusions:

• Third-generation EGFR TKIs represent a significant advancement in advanced EGFR+ NSCLC treatment.
• Ongoing clinical trials, particularly combination therapies, hold promise for future standard of care.
• The development pipeline is robust, suggesting continued progress in this field.